Le Lézard
Classified in: Health, Business
Subjects: TDS, CXP

Ganeden Continues Canadian Expansion with New Health Canada Approvals


CLEVELAND, Aug. 16, 2017 /PRNewswire/ -- As a result of recent regulatory work, Ganeden has made advancements for the usage of its patented and shelf-stable probiotic strain, GanedenBC30® (Bacillus coagulans GBI-30 6086), in Canada. The international leader in probiotic ingredients received a no objection letter from Health Canada, which provides further support for approved probiotic wording and allows Canadian companies fortifying with GanedenBC30® to make additional health claims.

GanedenBC30 (Bacillus coagulans GBI-30, 6086) is Ganeden's patented probiotic ingredient that can be found in more than 750 leading food, beverage, sports nutrition and companion animal products around the world. Unlike most other probiotic strains, GanedenBC30 is highly stable and remains viable through most manufacturing processes, three years of shelf life and the low pH of stomach acid. For more information, visit GanedenBC30.com

The no objection letter from Health Canada confirms that products fortified with GanedenBC30 can make any of the general health claims that are allowed in the country's probiotic monograph, and also provides opportunities for new gut flora language on packaging. This new approval makes it easier for companies to educate consumers on the benefits of GanedenBC30 on their food and beverage product packaging.

"Canada has become a strong market for probiotic fortification in foods and beverages, and we are dedicated to advancing regulatory approvals and probiotic language both there and internationally," said Dr. David Keller, vice president of scientific operations for Ganeden. "Our goal as a leader in the space is to make it as easy as possible for food and beverage manufacturers to fortify with a high-quality probiotic ingredient, and to also provide direction on probiotic-related health claims and educational content."

Probiotics are in high demand worldwide, and Canada is no exception. Ganeden is already a well-known name in the Canadian probiotic industry, partnering with many food and beverage manufacturers to fortify GanedenBC30 (Bacillus coagulans GBI-30 6086) into a variety of everyday products. The science-backed probiotic strain is best known for its efficacy and stability, which allows it to survive most manufacturing processes, shelf life and gastric transit?opening up endless opportunities for fortification in foods and beverages where other probiotic strains are often unable to survive.

Ganeden plans to continue its expansion and partnerships in the Canadian market, with multiple new probiotic products currently in development?many of which are expected to launch this year. Experts from the team will be exhibiting at Canadian Health Food Association (CHFA) East in Toronto (booth #2307), and will be available to discuss details. For more information on Ganeden, including its ingredient portfolio, research and international presence, visit GandedenProbiotics.com.

About Ganeden:

Ganeden® is at the forefront of probiotic research and product development with an extensive library of published studies and more than 135 patents for probiotic technologies in the supplement, food, beverage, animal health, sports nutrition and personal care ingredients markets. Ganeden is best known for GanedenBC30® its patented, FDA GRAS, highly stable probiotic ingredient. Through the fermentation process of GanedenBC30, Ganeden developed Bonicel®, the first science-backed, probiotic-derived, personal care ingredient shown to dramatically reduce signs of aging. Ganeden's newest ingredient, Staimunetm is a patented probiotic technology comprising of inactivated GanedenBC30 which has been shown to have immune benefits. For more information about Ganeden and licensing opportunities visit GanedenProbiotics.com.

About GanedenBC30:
GanedenBC30® (Bacillus coagulans GBI-30, 6086) is Ganeden's patented probiotic ingredient that can be found in more than 750 leading food, beverage, sports nutrition and companion animal products around the world. Unlike most other probiotic strains, GanedenBC30 is a spore-former which makes it highly stable and allows it to remain viable through most manufacturing processes, three years of shelf life and the low pH of stomach acid.  The efficacy of GanedenBC30 is backed by over 25 published studies showing safety, digestive and immune support, and protein utilization benefits. GanedenBC30 has an exceptional safety record with FDA GRAS status from the United States FDA. It can be formulated into virtually any food, beverage or companion animal product that is baked, boiled, frozen or squeezed.... including all hot or refrigerated beverages!  For more information, please visit GanedenBC30.com.

Ganeden is at the forefront of probiotic research and product development with an extensive library of published studies and more than 130 patents for probiotic technologies and ingredients in the food, beverage, animal health, sports nutrition and personal care ingredients markets. For more information, visit GanedenProbiotics.com.

SOURCE Ganeden


These press releases may also interest you

at 02:48
Today, RaySearch Laboratories AB (publ)  publishes its Annual Report for the financial year 2023. The report is held available on RaySearch's website, under the section Investors.  This information is information that RaySearch Larboratiories AB...

at 02:43
Shareholders of Zinzino AB (publ) are hereby invited to the annual general meeting on Monday, May 27, 2024, at 1:30 PM at the company's premises at Hulda Mellgrens gata 5 in Gothenburg. Registration begins at 1:15 PM. The company aims to webcast the...

at 02:41
Implantica AG (publ), a med-tech company at the forefront of bringing advanced technology into the body, is publishing its annual report for the fiscal year 2023. The annual report is now available on the company's website. "Implantica had a very...

at 02:08
Revenue amounted to ?498.8m (?419.3m), an increase of 18.9% with an organic growth of 14.2%.Operating profit (EBIT) was ?19.0m (?10.7m), an increase of 78.0%, representing an operating margin of 3.8% (2.6%).Net profit amounted to ?6.5m (?2.1m), which...

at 02:00
Amwins Global Risks is delighted to announce Classic Cars and Cotswolds, an auction to raise money for the Matthew Wilson Multiple Myeloma Fund at Blood Cancer UK. The online auction opens today and features Ferraris, Aston Martins, a Rolls Royce, a...

at 01:35
Regulatory News: Sensorion (FR0012596468 ? ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces...



News published on and distributed by: